 |
|
|
| |
Real-world effectiveness and safety of 8-week glecaprevir/pibrentasvir
for treatment-naïve patients from Taiwan nationwide HCV registry
|
| |
| |
EASL 2024 June 5-8 Milan, Italy
CF. Huang1,2, TS. Chang3,4, HT. Kuo5, CW. Huang6, LR. Mo7, CM. Tai8,9, KC. Tseng10,11, MJ. Bair12,13, SJ. Wang14, CC. Lo15, LW. Chong16,17, PN. Cheng18, ML. Yeh1,19, CY. Peng20,21, CY. Cheng22, JF. Huang1,23, CL. Lin24, CC. Yang25, TY. Hsieh26, TH. Lee27, PL. Lee28, WC. Wu29, CL. Lin30, WW. Su31, SS. Yang32,33,34, CC. Wang35, JT. Hu36, CT. Chen26,37, YH. Huang38,39, CC. Chang40,41, CS. Huang42, GY. Chen43, CN. Kao44, CJ. Liu45, MH Lee46, PC. Tsai1, CY. Dai1, JH. Kao45, HC. Lin38,39, WL. Chuang1, CH. Hung47, CY. Chen48, ML Yu1,19,23,47,49
|
| |
|
|
|
|
|
